2020年-中国新药License-out大爆发

Categories:最新消息
Author:华讯知识产权
Origin:
Time of issue:2020-11-06 15:09
Views:

(Summary description)一直以来，“创新药”都存在研发难度大、投入高、周期长等难题，但从长远来看，创新药的研发能力依旧是药企的核心竞争力。在推进中国创新药走向全球的过程中，一大批以创新研发为主的药企也在飞速发展。进入2020年以来，中国新药授权交易（License in/out）数量较前几年激增，尤其是我国创新药License-out合作授权数量明显增多，可谓是License-out大爆发的一年。 10月29日，复星医药宣布，其控股子公司复创医药已与礼来公司（Eli Lilly and Company）签订《许可协议》，授予礼来对复创医药BCL-2抑制剂FCN-338在除中国大陆、香港及澳门地区之外的全球其它区域的独家权益。合作涉及金额高达4.4亿美元。 10月27日，基石药业宣布，与EQRx公司达成战略合作。基石药业将独家授权EQRx公司在大中华区以外地区开发和商业化抗PD-L1单抗舒格利单抗（CS1001）及抗PD-1单抗CS1003。合作涉及金额高达13亿美元。 9月28日，恒瑞医药宣布，已与韩国HLB Life Science公司（简称“HLB-LS公司”）达成协议，以1.057亿美元交易总额，将其具有自主知识产权的抗肿瘤药品马来酸吡咯替尼片（简称“吡咯替尼”）项目有偿许可给韩国HLB-LS公司，并获得HLB-LS公司的销售分成。 9月4日，天境生物公司和艾伯维共同宣布，双方就由天境生物自主研发、用于治疗多种癌症的创新型CD47单克隆抗体lemzoparlimab（TJC4）的开发和商业化建立全球战略合作，合作总金额或近30亿美元，刷新中国创新药企产品权益转让纪录。 8月，信达生物宣布，将授予礼来达伯舒®（信迪利单抗注射液）在中国以外地区的独家许可，礼来将致力于将信迪利单抗推向北美、欧洲及其他地区。 6月9日，康宁杰瑞宣布，与赛诺菲已签署协议达成战略合作：将共同针对HER2阳性乳腺癌患者，推进KN026与泰索帝®(Docetaxel)联合用药的临床试验。根据协议条款，在达到特定临床里程碑后，赛诺菲将有权在独占期内协商获得KN026的独家许可引进权。 6月1日，加科思宣布，与艾伯维达成一项授权交易。根据协议，双方将共同开发和商业化作用于癌细胞和免疫细胞关键靶点的蛋白酪氨酸磷酸酶（SHP2）抑制剂，艾伯维将获得加科思SHP2项目的独家许可权。 5月4日，君实生物宣布，与礼来公司（Eli Lilly and Company）签署了《研发合作和许可协议》，双方将合作研发及商业化SARS-CoV-2中和抗体（简称：君实新冠抗体，产品代号：JS016）。根据协议，礼来公司将被授予在大中华地区外对JS016开展研发活动、生产和销售的独占许可。合作涉及金额2.55亿美元。 4月20日，恒瑞医药宣布，与韩国CrystalGenomics Inc.公司签署协议，以8775万美元交易总额将PD-1单克隆抗体卡瑞利珠项目许可给CG公司，同时获得CG公司的销售分成，CG公司将获得卡瑞利珠单抗在韩国的独家临床开发、注册和市场销售的权利，被许可进行研发和销售卡瑞利珠单抗用于所有人类疾病。 4月15日，LEO Pharma宣布，与合一生技（Oneness Biotech）和中天（上海）生物（Microbio Shanghai）签署了全球独家许可协议，获得合一生技旗下一款抗体候选药物FB825的开发和商业化权益。根据协议，LEO Pharma将支付4000万美元的预付款，并提供最高5.3亿美元的里程碑付款，以及后续潜在的特许权使用费。 4月8日，成都先导宣布，与田边三菱制药株式会社（简称“MTPC”）达成一项新药研发转让协议。该转让协议囊括了一系列全新结构的小分子先导化合物，具体靶点是由MTPC指定的未披露靶点。按照协议约定，MTPC将向成都先导支付转让费，而成都先导将这些小分子化合物的后续开发及商业化权益排他性地转让于MTPC。 3月31日，复宏汉霖宣布，与Mabxience Research, S.L.订立独家许可协议。授予Mabxience在阿根廷、乌拉圭及巴拉圭就肿瘤治疗开发和商业化HLX02产品的独家许可。合作涉及金额75万美元。 3月11日，成都先导宣布，与日本科研制药株式会社（Kaken Pharmaceutical Co. Ltd.，简称Kaken）达成一项新药研发转让协议。按照协议约定，Kaken将向成都先导支付转让费，而成都先导将这些小分子化合物的后续开发及商业化权益排他性地转让于Kaken。 1月14日，信达生物宣布，将贝伐珠单抗生物类似药（IBI305）在美国和加拿大的商业化权益授权给Coherus BioSciences。合作涉及金额4500万美元。本土药企license out交易数量的逐年增加，反映了中国本土药企的研发实力在逐渐增强。

2020年-中国新药License-out大爆发

(Summary description)一直以来，“创新药”都存在研发难度大、投入高、周期长等难题，但从长远来看，创新药的研发能力依旧是药企的核心竞争力。在推进中国创新药走向全球的过程中，一大批以创新研发为主的药企也在飞速发展。进入2020年以来，中国新药授权交易（License in/out）数量较前几年激增，尤其是我国创新药License-out合作授权数量明显增多，可谓是License-out大爆发的一年。

10月29日，复星医药宣布，其控股子公司复创医药已与礼来公司（Eli Lilly and Company）签订《许可协议》，授予礼来对复创医药BCL-2抑制剂FCN-338在除中国大陆、香港及澳门地区之外的全球其它区域的独家权益。合作涉及金额高达4.4亿美元。

10月27日，基石药业宣布，与EQRx公司达成战略合作。基石药业将独家授权EQRx公司在大中华区以外地区开发和商业化抗PD-L1单抗舒格利单抗（CS1001）及抗PD-1单抗CS1003。合作涉及金额高达13亿美元。

9月28日，恒瑞医药宣布，已与韩国HLB Life Science公司（简称“HLB-LS公司”）达成协议，以1.057亿美元交易总额，将其具有自主知识产权的抗肿瘤药品马来酸吡咯替尼片（简称“吡咯替尼”）项目有偿许可给韩国HLB-LS公司，并获得HLB-LS公司的销售分成。

9月4日，天境生物公司和艾伯维共同宣布，双方就由天境生物自主研发、用于治疗多种癌症的创新型CD47单克隆抗体lemzoparlimab（TJC4）的开发和商业化建立全球战略合作，合作总金额或近30亿美元，刷新中国创新药企产品权益转让纪录。

8月，信达生物宣布，将授予礼来达伯舒®（信迪利单抗注射液）在中国以外地区的独家许可，礼来将致力于将信迪利单抗推向北美、欧洲及其他地区。

6月9日，康宁杰瑞宣布，与赛诺菲已签署协议达成战略合作：将共同针对HER2阳性乳腺癌患者，推进KN026与泰索帝®(Docetaxel)联合用药的临床试验。根据协议条款，在达到特定临床里程碑后，赛诺菲将有权在独占期内协商获得KN026的独家许可引进权。

6月1日，加科思宣布，与艾伯维达成一项授权交易。根据协议，双方将共同开发和商业化作用于癌细胞和免疫细胞关键靶点的蛋白酪氨酸磷酸酶（SHP2）抑制剂，艾伯维将获得加科思SHP2项目的独家许可权。

5月4日，君实生物宣布，与礼来公司（Eli Lilly and Company）签署了《研发合作和许可协议》，双方将合作研发及商业化SARS-CoV-2中和抗体（简称：君实新冠抗体，产品代号：JS016）。根据协议，礼来公司将被授予在大中华地区外对JS016开展研发活动、生产和销售的独占许可。合作涉及金额2.55亿美元。

4月20日，恒瑞医药宣布，与韩国CrystalGenomics Inc.公司签署协议，以8775万美元交易总额将PD-1单克隆抗体卡瑞利珠项目许可给CG公司，同时获得CG公司的销售分成，CG公司将获得卡瑞利珠单抗在韩国的独家临床开发、注册和市场销售的权利，被许可进行研发和销售卡瑞利珠单抗用于所有人类疾病。

4月15日，LEO Pharma宣布，与合一生技（Oneness Biotech）和中天（上海）生物（Microbio Shanghai）签署了全球独家许可协议，获得合一生技旗下一款抗体候选药物FB825的开发和商业化权益。根据协议，LEO Pharma将支付4000万美元的预付款，并提供最高5.3亿美元的里程碑付款，以及后续潜在的特许权使用费。

4月8日，成都先导宣布，与田边三菱制药株式会社（简称“MTPC”）达成一项新药研发转让协议。该转让协议囊括了一系列全新结构的小分子先导化合物，具体靶点是由MTPC指定的未披露靶点。按照协议约定，MTPC将向成都先导支付转让费，而成都先导将这些小分子化合物的后续开发及商业化权益排他性地转让于MTPC。

3月31日，复宏汉霖宣布，与Mabxience Research, S.L.订立独家许可协议。授予Mabxience在阿根廷、乌拉圭及巴拉圭就肿瘤治疗开发和商业化HLX02产品的独家许可。合作涉及金额75万美元。

3月11日，成都先导宣布，与日本科研制药株式会社（Kaken Pharmaceutical Co. Ltd.，简称Kaken）达成一项新药研发转让协议。按照协议约定，Kaken将向成都先导支付转让费，而成都先导将这些小分子化合物的后续开发及商业化权益排他性地转让于Kaken。

1月14日，信达生物宣布，将贝伐珠单抗生物类似药（IBI305）在美国和加拿大的商业化权益授权给Coherus BioSciences。合作涉及金额4500万美元。

本土药企license out交易数量的逐年增加，反映了中国本土药企的研发实力在逐渐增强。

Categories:最新消息
Author:华讯知识产权
Origin:
Time of issue:2020-11-06 15:09
Views:

Information

一直以来，“创新药”都存在研发难度大、投入高、周期长等难题，但从长远来看，创新药的研发能力依旧是药企的核心竞争力。在推进中国创新药走向全球的过程中，一大批以创新研发为主的药企也在飞速发展。进入2020年以来，中国新药授权交易（License in/out）数量较前几年激增，尤其是我国创新药License-out合作授权数量明显增多，可谓是License-out大爆发的一年。

10月29日，复星医药宣布，其控股子公司复创医药已与礼来公司（Eli Lilly and Company）签订《许可协议》，授予礼来对复创医药BCL-2抑制剂FCN-338在除中国大陆、香港及澳门地区之外的全球其它区域的独家权益。合作涉及金额高达4.4亿美元。

10月27日，基石药业宣布，与EQRx公司达成战略合作。基石药业将独家授权EQRx公司在大中华区以外地区开发和商业化抗PD-L1单抗舒格利单抗（CS1001）及抗PD-1单抗CS1003。合作涉及金额高达13亿美元。

9月28日，恒瑞医药宣布，已与韩国HLB Life Science公司（简称“HLB-LS公司”）达成协议，以1.057亿美元交易总额，将其具有自主知识产权的抗肿瘤药品马来酸吡咯替尼片（简称“吡咯替尼”）项目有偿许可给韩国HLB-LS公司，并获得HLB-LS公司的销售分成。

9月4日，天境生物公司和艾伯维共同宣布，双方就由天境生物自主研发、用于治疗多种癌症的创新型CD47单克隆抗体lemzoparlimab（TJC4）的开发和商业化建立全球战略合作，合作总金额或近30亿美元，刷新中国创新药企产品权益转让纪录。

8月，信达生物宣布，将授予礼来达伯舒®（信迪利单抗注射液）在中国以外地区的独家许可，礼来将致力于将信迪利单抗推向北美、欧洲及其他地区。

6月9日，康宁杰瑞宣布，与赛诺菲已签署协议达成战略合作：将共同针对HER2阳性乳腺癌患者，推进KN026与泰索帝®(Docetaxel)联合用药的临床试验。根据协议条款，在达到特定临床里程碑后，赛诺菲将有权在独占期内协商获得KN026的独家许可引进权。

6月1日，加科思宣布，与艾伯维达成一项授权交易。根据协议，双方将共同开发和商业化作用于癌细胞和免疫细胞关键靶点的蛋白酪氨酸磷酸酶（SHP2）抑制剂，艾伯维将获得加科思SHP2项目的独家许可权。

5月4日，君实生物宣布，与礼来公司（Eli Lilly and Company）签署了《研发合作和许可协议》，双方将合作研发及商业化SARS-CoV-2中和抗体（简称：君实新冠抗体，产品代号：JS016）。根据协议，礼来公司将被授予在大中华地区外对JS016开展研发活动、生产和销售的独占许可。合作涉及金额2.55亿美元。

4月20日，恒瑞医药宣布，与韩国CrystalGenomics Inc.公司签署协议，以8775万美元交易总额将PD-1单克隆抗体卡瑞利珠项目许可给CG公司，同时获得CG公司的销售分成，CG公司将获得卡瑞利珠单抗在韩国的独家临床开发、注册和市场销售的权利，被许可进行研发和销售卡瑞利珠单抗用于所有人类疾病。

4月15日，LEO Pharma宣布，与合一生技（Oneness Biotech）和中天（上海）生物（Microbio Shanghai）签署了全球独家许可协议，获得合一生技旗下一款抗体候选药物FB825的开发和商业化权益。根据协议，LEO Pharma将支付4000万美元的预付款，并提供最高5.3亿美元的里程碑付款，以及后续潜在的特许权使用费。

4月8日，成都先导宣布，与田边三菱制药株式会社（简称“MTPC”）达成一项新药研发转让协议。该转让协议囊括了一系列全新结构的小分子先导化合物，具体靶点是由MTPC指定的未披露靶点。按照协议约定，MTPC将向成都先导支付转让费，而成都先导将这些小分子化合物的后续开发及商业化权益排他性地转让于MTPC。

3月31日，复宏汉霖宣布，与Mabxience Research, S.L.订立独家许可协议。授予Mabxience在阿根廷、乌拉圭及巴拉圭就肿瘤治疗开发和商业化HLX02产品的独家许可。合作涉及金额75万美元。

3月11日，成都先导宣布，与日本科研制药株式会社（Kaken Pharmaceutical Co. Ltd.，简称Kaken）达成一项新药研发转让协议。按照协议约定，Kaken将向成都先导支付转让费，而成都先导将这些小分子化合物的后续开发及商业化权益排他性地转让于Kaken。

1月14日，信达生物宣布，将贝伐珠单抗生物类似药（IBI305）在美国和加拿大的商业化权益授权给Coherus BioSciences。合作涉及金额4500万美元。

本土药企license out交易数量的逐年增加，反映了中国本土药企的研发实力在逐渐增强。

Keyword:

Previous: 保守派大法官巴雷特就任美国最高法院，她是如何看待美国热点知识产权问题？

Next: 最高法院就《关于审理涉药品上市审评审批专利民事案件适用法律若干问题的规定》发布征求意见稿，有哪些新规定值得关注？

Previous: 保守派大法官巴雷特就任美国最高法院，她是如何看待美国热点知识产权问题？

Next: 最高法院就《关于审理涉药品上市审评审批专利民事案件适用法律若干问题的规定》发布征求意见稿，有哪些新规定值得关注？

Electronic Arts pledges free use for five accessibility patents

Electronic Arts pledges free use for five accessibility patents Recently, Electronic Arts (EA) announced a patent pledge that gives other companies and developers free access to five of its current accessibility-related patents and technology. The company promised not to enforce against any party for infringing any of the listed patents. Instead, EA hopes to encourage “innovation” and build new features that make video games more inclusive on a much larger scale by opening up the patents. Electronic Arts (EA) is an American video game company founded in 1982. The company owns many popular and famous games, such as The Sims, SimCity, Apex Legends, Madden NFL and FIFA. Each of the games has more than 30 or 50 million sales volume. Significantly, esports involves FIFA and Apex Legends into the event list. Apex Legends has up to 1 billion players, and it is so popular that it has a Switch version. Within the freely available patents, one of which grabs everyone’s attention -- Apex Legends’ ping system (patent No. US 11097189). The ping system in Apex Legends, which excellently allows players to make communication and teamwork quick and easy without hearing or speaking, has been praised both as an impressive alternative to voice chat and as a great accessibility feature for players with a variety of disabilities. The other patents include the technology widely used in the FIFA and Madden NFL. The innovations can automatically detect and modify colors (patent No. US 10118097 and CN 107694092) and contrast ratios (patent No. US 10878540) to improve gamers’ visibility with colorblindness and low vision. Furthermore, one of the patents relates to personalized sound technology, helping players with hearing issues by modifying or creating music based on their preferences (patent No. US 10790919). The code of the mentioned technology is published on EA’s GitHub, and it is open to all developers. Thus, the developers can use it or adapt it for their games without spending the costs to research. It is good that EA shares the patents for free use and aims to create an accessibility-increased gaming environment for players. However, it is not “unconditional” to use the listed patents. In the pledge, EA mentioned that it may terminate the promise for a specific party which files a patent infringement lawsuit or other patent proceedings against EA. We can see parts of EV’s ambition behind the announcement—to build a large game developer league and a community of shared interests. Reference: https://www.ea.com/commitments/positive-play/accessibility-patent-pledge https://iknow.stpi.narl.org.tw/Post/Read.aspx?PostID=14562 https://www.polygon.com/22639469/apex-legends-electronic-arts-patent-pledge-accessibility-developers https://www.theverge.com/2021/8/24/22638535/ea-accessibility-patent-pledge-apex-legends-ping-system https://www.gamesradar.com/ea-secures-a-patent-for-the-apex-legends-ping-system-and-its-giving-it-away-for-free/ https://dotesports.com/apex-legends/news/apex-legends-ping-system-is-now-patent-free-for-accessibility https://www.nintendolife.com/news/2021/08/apex_legends_ping_system_now_patent-free_as_ea_announces_accessibility_pledge Recently, Electronic Arts (EA) announced a patent pledge that gives other companies and developers free access to five of its current accessibility-related patents and technology. The company promised not to enforce against any party for infringing any of the listed patents. Instead, EA hopes to encourage “innovation” and build new features that make video games more inclusive on a much larger scale by opening up the patents. Electronic Arts (EA) is an American video game company founded in 1982. The company owns many popular and famous games, such as The Sims, SimCity, Apex Legends, Madden NFL and FIFA. Each of the games has more than 30 or 50 million sales volume. Significantly, esports involves FIFA and Apex Legends into the event list. Apex Legends has up to 1 billion players, and it is so popular that it has a Switch version. Within the freely available patents, one of which grabs everyone’s attention -- Apex Legends’ ping system (patent No. US 11097189). The ping system in Apex Legends, which excellently allows players to make communication and teamwork quick and easy without hearing or speaking, has been praised both as an impressive alternative to voice chat and as a great accessibility feature for players with a variety of disabilities. The other patents include the technology widely used in the FIFA and Madden NFL. The innovations can automatically detect and modify colors (patent No. US 10118097 and CN 107694092) and contrast ratios (patent No. US 10878540) to improve gamers’ visibility with colorblindness and low vision. Furthermore, one of the patents relates to personalized sound technology, helping players with hearing issues by modifying or creating music based on their preferences (patent No. US 10790919). The

2021-10-22

The forum on "China's Intellectual Property-related Reform Measures and New Trends in Patent Litigation" will be held successfully!

The forum on "China's Intellectual Property-related Reform Measures and New Trends in Patent Litigation" will be held successfully! In response to the call for building a strong country with intellectual property rights, at 2 o'clock in the afternoon of October 21, the forum on "China's reform measures related to intellectual property rights and new trends in patent litigation" will be successfully held in Nanjing Jiangbei New District Industrial Technology Research and Innovation Park. The event was hosted by the Science and Technology Innovation Bureau of Nanjing Jiangbei New Area Management Committee, Nanjing Jiangbei New Area Industrial Technology Research and Innovation Park, Nanjing Intellectual Property Rights Protection Assistance Center Jiangbei New District Center, Nanjing Huaxun Intellectual Property Consultant Co., Ltd., Nanjing Intellectual Property Co-organized by the Protection Center (Nanjing Intellectual Property Rights Protection Assistance Center), Taiwan Pharmaceutical Development Association, and Gene Online. The director of Nanjing Intellectual Property Protection Center, Mou Xiaojian, delivered a speech. Director Mu expressed his warm congratulations on the holding of this event and introduced in detail the new pattern of intellectual property protection in Nanjing. He said: At present, Nanjing has implemented a rights protection assistance network in the municipal area. With full coverage, Nanjing Intellectual Property Protection Center is willing to closely communicate and interact with Nanjing's innovation entities, and provide relevant public welfare services such as rapid pre-review, rapid rights protection, and comprehensive utilization for enterprises in need. In addition, Huang Funan, CEO of Gene Online, was unable to come to congratulate due to the epidemic, and recorded a congratulatory video. In the video, he said: China Innovative Pharmaceuticals has already made many outstanding achievements on the international stage, and these are inseparable from intellectual property rights. The support of the company can also show the importance of intellectual property rights to biotechnology and pharmaceutical companies. This event invites four industry experts to focus on China's reform measures related to intellectual property rights and new trends in patent litigation, discuss with companies and universities, and make arrangements in advance. Dr. Qingchen Hou, general manager of Nanjing Huaxun Intellectual Property Consulting Co., Ltd., introduced the "Guidelines for Building a Powerful Country with Intellectual Property Rights (2021-2035)" and explained his views from four aspects: background, strategic layout, overall requirements, and organizational guarantees. . Subsequently, a detailed analysis of China's patent linkage system was carried out, and compared with the same types of cases at home and abroad, questions were raised: Why should we reward the first person who successfully challenged patents? Not the first person to file a P4 application? And have a series of discussions with you. Director Jiang Haijun of the Intellectual Property Protection Legal Committee of the Nanjing Lawyers Association gave a speech on three points: the problems after the amendment of the patent law, the enforceability of the amount of compensation, and the legal conflicts related to service inventions. Regarding the patent right evaluation report, he emphasized that the patentee, interested party or accused infringer can also proactively issue a patent right evaluation report. "Patent is a work of art that combines technology and law" is a message shared by Mr. Feng Tao from Jiangsu Junbo Law Firm at this event. Mr. Feng analyzes the big data of Chinese patent litigation cases through graphs and examples. Explore. The last topic of the event was shared by Guo Huangying, Intellectual Property Manager of Nanjing Huaxun Intellectual Property Agency (General Partnership)-China's Patent Infringement Judgment Principles and New Developments. Manager Guo explained to everyone the principles of patent infringement judgment and the necessity of patent infringement search and analysis before producing and selling products. In the intellectual property industry, ECCOM has been providing high-quality and professional comprehensive intellectual property services to enterprises and universities one step at a time. It also hopes that under the leadership of the state and the government, it will contribute to the building of a strong intellectual property nation in China. Make a contribution.

2021-10-22

Types of patents that are easily overlooked- Design Patent

Types of patents that are easily overlooked- Design Patent In recent years, as the public’s awareness of intellectual property has increased, people have begun to consciously use the patent law to protect their intellectual property rights. However, in the process of implementation, they often only focus on invention patent and utility model patent, and tend to ignore the protection of design patent. Recently, Midea sued Haotaitai for two models of CXW-300-D998 and CXW-300-D908 Haotaitai brand range hoods In the case of suspected infringement of its design patent (patent number: ZL201930621598.X), the Guangzhou Intellectual Property Court made a first-instance judgment after hearing that it determined that the two products of Haotaitai constituted infringement, and ordered it to immediately stop the infringement and compensate Midea, The company's economic losses and reasonable expenses totaled 360,000 yuan. In fact, appearance infringement cases have occurred from time to time before, such as: "Molly" blind box design patent case, "Siemens" switch design patent infringement dispute case received a compensation of 6 million yuan, three Casio watch design patents were infringed Received a compensation of 8.8 million yuan and so on. The reason why people ignore the protection of design patents, in the final analysis, is that they have insufficient knowledge of design patents. Today, let's take a look at what is protected by design patents and what rights protections can we apply for? Design patent definition: Article 2 of the "Patent Law", design patent, refers to a new design that is aesthetically pleasing and suitable for industrial applications based on the shape, pattern, or combination of products, and the combination of color, shape, and pattern. Protected range: The shape of the product; the pattern of the product; the shape and pattern of the product; the shape and color of the product; the pattern and color of the product; the shape, pattern and color of the product. Protection period: The term of protection for design patent rights is 15 years, calculated from the date of filing. What are the conditions for applying for a design patent? The design should be aesthetically pleasing Appearance patents should be suitable for industrial applications The design patent application should be novel The design patent application should be inventiveness What are the advantages and functions of design patents? Protect the rights and interests of enterprises in product designs and fight against infringements in market competition. To enhance brand value, the quality and quantity of patents are the embodiment of the company's innovation ability and core competitiveness. Receive consumer recognition. If a company's new product appearance is filed for a patent in a timely manner, its appearance design will enjoy the exclusive right. Nowadays, consumers often choose products with trendy and beautiful appearance when buying their products. Applying for a design patent is a necessary condition for applying for a high-tech enterprise.

2021-09-26

Colopl Settles Patent Infringement Lawsuit with Nintendo by Paying $30 Million

Colopl Settles Patent Infringement Lawsuit with Nintendo by Paying $30 Million This August, Nintendo and a game developer Colopl announced that they have settled for patent infringement regarding White Cat Project (Shironeko Project in Japanese), a smartphone game developed by Colopl. Although both companies did not publicly share exact details of the settlement, at least it is sure that Colopl agreed to pay 3.3 billion yen (about US$30.2 million) as the settlement fee for the proceedings, including the future license of Nintendo's patents. How did the battle begin? Being developed and published by a Japanese game developer, Colopl, White Cat Project is a free-to-play action role-playing game for Android and iOS systems. The mobile game was launched in July 2014 as well as got a television anime adaptation in 2020. It is incredibly popular to have more than 50 million downloads. Furthermore, the game is set to receive a Switch version titled "Shironeko New Project". In September 2016, Nintendo noted the Colopl's game and considered that the game had infringed on several of Nintendo's technology patents. The two companies communicated with each other for over a year; however, Nintendo did not accept the explanations from Colopl, and Nintendo filed a lawsuit against Colopl at the beginning of 2018. Nintendo claimed that Colopl infringed 6 of its patents. These patents protect touch-screen joystick functionality (patent no. JP3734820), multiplayer connectivity (patent no. JP5595991, JP6271692), confirmation screens in sleep mode (patent no. JP4010533), character attacks based on touch input locations (patent no. JP4262217), and a shadow effect placed on characters hidden behind the game geometry (patent no. JP3637031). These patents almost cover various ways of game technology, especially the patent JP5595991 and JP6271692. Their patent family is wide-reaching, and many divisional applications of the family are pending in Japan. They protect a communication game system and its related devices. It is not easy to detect the patent's existence and boundary since this kind of hardcore technique is so common in the gaming field and our daily lives. The five-year patent war has been settled. After a five-year dispute, the situation appeared to turn in Nintendo's favor as the Switch maker increased its monetary demands, which convinced Colopl to strike a deal that lets it use the disputed patents. Furthermore, a Switch version of White Cat Project remains in the works at Colopl. With the extraordinary losses of Colopl, the legal battle between the two companies came to an end.

2021-09-09